Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 4/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LAP3 | P28838 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754171 | 0.98 | TP53 (0.48) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL754167 | 0.98 | TP53 (0.48) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL27960179 | 0.98 | TP53 (0.48) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL27731097 | 0.96 | TP53 (0.47) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL420985 | 0.93 | TP53 (0.42) | TP53FDPSCA1RECQL | |
| SCHEMBL28560310 | 0.87 | TP53 (0.47) | TP53FDPSSMPD1GPR84 | |
| SCHEMBL5456959 | 0.85 | TP53 (0.48) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL37544 | 0.84 | HDAC1 (0.39) | TP53FDPSCA1RECQL | |
| SCHEMBL5461425 | 0.83 | TP53 (0.47) | TP53FDPSSMPD1GPR84CA1 | |
| SCHEMBL8372616 | 0.83 | TP53 (0.47) | TP53FDPSSMPD1GPR84CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | claimed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | claimed |
| US-9085525-B2 | Processes employing cyclodextrin derivative quaternary salts | MATOS JOSE R (US) | 2015-07-21 | — | — | US | claimed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | claimed |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | MATOS JOSE R (US) | 2014-02-13 | — | — | US | claimed |
| US-8343995-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | claimed |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | claimed |
| JP-2010525083-A | — | — | 2010-07-22 | — | — | JP | claimed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | claimed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| WO-2008134601-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| EP-1742535-A4 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2008-10-15 | — | — | EP | claimed |
| US-20070175472-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2007-08-02 | — | — | US | claimed |
| EP-1755551-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1742535-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005117911-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | claimed |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | claimed |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260091073-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4620534-A2 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12390506-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4591858-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3939582-B1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | KIORA PHARMACEUTICALS PTY LTD (AU) | 2024-10-31 | — | — | US | disclosed |
| US-20240009151-A1 | FORMULATIONS OF AZOBENZENE PHOTOREACTIVE COMPOUNDS | BAYON THERAPEUTICS, INC. | 2024-01-11 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11806402-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| CN-116869983-A | Formulations comprising acetaminophen and sulfoalkyl ether cyclodextrin | 锡德克斯药物公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-116829191-A | Formulations of azobenzene photoreactive compounds | 巴约治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-3766493-B1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230255919-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-08-17 | — | — | US | disclosed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230233638-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | UNIVERSITY OF KANSAS | 2023-07-27 | — | — | US | disclosed |
| CN-110831588-B | Composition comprising cyclodextrin and busulfan | 锡德克斯药物公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230002513-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20220387444-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-12-08 | — | — | US | disclosed |
| EP-4083075-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-27 | — | — | US | disclosed |
| US-20220332853-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-20 | — | — | US | disclosed |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| CN-115038723-A | Alkylated cyclodextrin compositions and methods of making and using the same | 锡德克斯药物公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11433082-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11382944-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| CN-110066351-B | Alkylated cyclodextrin compositions and methods of making and using the same | 锡德克斯药物公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114053423-A | Sulfoalkyl ether cyclodextrin compositions | 锡德克斯药物公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3939582-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| EP-3520779-B1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3270941-B1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210093727-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| EP-3766493-A1 | METHOD FOR IMPROVING THE STABILITY OF CLOPIDOGREL USING SULFOALKYL ETHER CYCLODEXTRIN | CyDex Pharmaceuticals, Inc. (US) | 2021-01-20 | — | — | EP | disclosed |
| EP-2152078-B1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS INC (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200330539-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-10-22 | — | — | US | disclosed |
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10780177-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200276314-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-09-03 | — | — | US | disclosed |
| US-10703826-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702568-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200179400-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2020-06-11 | — | — | US | disclosed |
| US-10668160-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3618825-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | Cydex Pharmaceuticals, Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110831588-A | Composition comprising cyclodextrin and busulfan | 锡德克斯药物公司 | 2020-02-21 | — | — | CN | disclosed |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2019-12-24 | — | — | US | disclosed |
| EP-3100728-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10463677-B2 | Composition containing sulfoalkyl ether cyclodextrin and latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190255000-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | US | disclosed |
| EP-3520779-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CyDex Pharmaceuticals, Inc. (US) | 2019-08-07 | — | — | EP | disclosed |
| CN-104800210-B | Preparation comprising clopidogrel and sulfoalkyl ether cyclodextrin and its application method | 锡德克斯药物公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-3512511-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190192684-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190169316-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-06-06 | — | — | US | disclosed |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | disclosed |
| US-20190070303-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-03-07 | — | — | US | disclosed |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10202468-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2708225-B1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CYDEX PHARMACEUTICALS INC (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10159752-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2018-12-25 | — | — | US | disclosed |
| US-20180326090-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180318249-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CYDEX PHARMACEUTICALS INC (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2018204535-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-08 | — | — | WO | disclosed |
| US-10117951-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10117940-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3363430-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| CN-104606681-B | Include the pharmaceutical composition and its preparation and application of prasugrel and cyclodextrine derivatives | 锡德克斯药物公司 | 2018-08-21 | — | — | CN | disclosed |
| US-10034947-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180154015-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-06-07 | — | — | US | disclosed |
| US-20180133274-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2018-05-17 | — | — | US | disclosed |
| WO-2018053358-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| EP-3270941-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9827324-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2994109-B1 | AQUEOUS OPHTHALMIC FORMULATIONS BASED ON AZITHROMYCIN | MEDIVIS S R L (IT) | 2017-11-01 | — | — | EP | disclosed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9750822-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170172926-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-06-22 | — | — | US | disclosed |
| US-20170173178-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-06-22 | — | — | US | disclosed |
| EP-2952197-B1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2017-04-26 | — | — | EP | disclosed |
| US-9623045-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9617352-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-01-12 | — | — | US | disclosed |
| EP-3100728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | Cydex Pharmaceuticals, Inc. (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20160346405-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-12-01 | — | — | US | disclosed |
| WO-2016149685-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| US-9399067-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2429291-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160158384-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-06-09 | — | — | US | disclosed |
| EP-2994109-A1 | AQUEOUS OPHTHALMIC FORMULATIONS BASED ON AZITHROMYCIN | Medivis S.R.L. (IT) | 2016-03-16 | — | — | EP | disclosed |
| US-20160058786-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2016-03-03 | — | — | US | disclosed |
| EP-2952197-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | Cydex Pharmaceuticals, Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9200088-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-9125945-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| CN-104800210-A | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS INC | 2015-07-29 | — | — | CN | disclosed |
| CN-104606681-A | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| EP-2335707-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2015-05-06 | — | — | EP | disclosed |
| CN-101686681-B | Formulations comprising clopidogrel and sulfoalkyl ether cyclodextrins and methods of use thereof | CYDEX PHARMACEUTICALS INC | 2015-04-01 | — | — | CN | disclosed |
| EP-1945228-B9 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| US-20150050355-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-02-19 | — | — | US | disclosed |
| CN-102625658-B | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS INC | 2015-01-28 | — | — | CN | disclosed |
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-22 | — | — | US | disclosed |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2015-01-01 | — | — | US | disclosed |
| EP-2581078-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-1945228-B2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2583668-B1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8853236-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846901-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8835407-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-8829182-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2173169-B1 | NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2708225-A1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CyDex Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130303498-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2013-11-14 | — | — | US | disclosed |
| US-20130288054-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2013-10-31 | — | — | US | disclosed |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130184357-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2583668-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2581078-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8410077-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20130059826-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-8383606-B2 | — | — | 2013-02-26 | — | — | US | disclosed |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CYDEX PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8343995-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYDEX PHARMACEUTICALS, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-8236782-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20120164184-A1 | DPI Formulation Containing Sulfoalkyl Ether Cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120136072-A1 | Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof | CYDEX PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2429291-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CyDex Pharmaceuticals, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-8114438-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20120021013-A1 | Composition Containing Sulfoalkyl Ether Cyclodextrin and Latanoprost | CYDEX PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8049003-B2 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CYDEX PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110251157-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110224232-A1 | Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2335707-A1 | Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof | CyDex Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110123518-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CYDEX PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-1945228-B1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX PHARMACEUTICALS INC (US) | 2011-04-06 | — | — | EP | disclosed |
| US-20110008325-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension | CYDEX PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2268269-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CyDex Pharmaceuticals, Inc. (US) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010132711-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2010-11-18 | — | — | US | disclosed |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYDEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010053487-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | CYDEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| EP-2173169-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CyDex Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-2152078-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CyDex Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7635773-B2 | Sulfoalkyl ether cyclodextrin compositions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7629331-B2 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2009137611-A2 | TREATMENT OF PULMONARY FUNGAL INFECTION WITH VORICONAZOLE VIA INHALATION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009134347-A2 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-10-29 | — | — | US | disclosed |
| US-20090123540-A1 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | CYDEX PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-2043599-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009018069-A2 | MIXTURES OF CYCLODEXTRIN DERIVATIVES | CYDEX PHARMACEUTICALS, INC (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20090011037-A1 | Improved flow and dissolution performance; use as solubilizer or stabilizer for drug formulations | CYDEX PHARMACEUTICALS, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2009003199-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008134600-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008134601-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1742535-A4 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1732512-A4 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1945228-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CyDex Pharmaceuticals, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1729724-A4 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | disclosed |
| EP-1718276-A4 | INHALANT FORMULATION CONTAINING SULFOALKYLETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX INC (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2008005692-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER γ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005802-A2 | NASAL FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005819-A2 | OPHTHALMIC FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005053-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008005691-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070202054-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070175472-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007050075-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | CYDEX, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1755551-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070020299-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070020196-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | disclosed |
| EP-1742535-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | Cydex Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1732512-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1729724-A1 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| EP-1718276-A2 | INHALANT FORMULATION CONTAINING SULFOALKYLETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | Cydex Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005117911-A2 | TASTE-MASKED FORMULATIONS CONTAINING SERTRALINE AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005104712-A2 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | CYDEX, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2005065435-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. ET AL. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065435-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. ET AL. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065651-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID PREPARED FROM A UNIT DOSE SUSPENSION | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065649-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER Ϝ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318249-A1 | COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN | SBDS, HBG1, CD99 | TP53 1079/4885FDPS 2231/4885SMPD1 1624/4885 |
| US-20170007586-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885FDPS 10/4885SMPD1 138/4885 |
| US-20130303498-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-10702568-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | GYS2, SDCBP, PYGL | TP53 181/4885FDPS 2767/4885SMPD1 192/4885 |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | PDE6C, ALDH1A2, PDE6D | TP53 4772/4885FDPS 570/4885SMPD1 343/4885 |
| US-20090011037-A1 | Improved flow and dissolution performance; use as solubilizer or stabilizer for drug formulations | ABCB11, SAE1, TBCD | TP53 610/4885FDPS 948/4885SMPD1 97/4885 |
| US-20170173178-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20150025243-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20220387444-A1 | COMPOSITION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND LATANOPROST | DSC1, CRYZ, TBCD | TP53 1367/4885FDPS 1405/4885SMPD1 128/4885 |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CRH, HRH1, IL5 | TP53 3704/4885FDPS 3213/4885SMPD1 598/4885 |
| US-20110251157-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20150005341-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING PRASUGREL AND CYCLODEXTRIN DERIVATIVES AND METHODS OF MAKING AND USING THE SAME | P2RY6, GP6, PFKP | TP53 2392/4885FDPS 10/4885SMPD1 138/4885 |
| US-20130197105-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | DSP, DSC1, SAE1 | TP53 1837/4885FDPS 2349/4885SMPD1 219/4885 |
| US-20200276314-A1 | DPI FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN | DSP, DSC1, SAE1 | TP53 1837/4885FDPS 2349/4885SMPD1 219/4885 |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | TP53 2498/4885FDPS 129/4885SMPD1 3694/4885 |
| US-20130012534-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885FDPS 10/4885SMPD1 138/4885 |
| US-11382944-B2 | Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same | GYS2, SDCBP, PYGL | TP53 181/4885FDPS 2767/4885SMPD1 192/4885 |
| US-20090123540-A1 | Sulfoalkyl ether cyclodextrin; use in pharmaceutical dosage forms as solubilizer or stabilizer | PDCD2L, SULT2A1, TBCD | TP53 826/4885FDPS 1288/4885SMPD1 363/4885 |
| US-20190255000-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | TP53 1441/4885FDPS 643/4885SMPD1 2515/4885 |
| US-10111863-B2 | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same | P2RY6, GP6, PFKP | TP53 2392/4885FDPS 10/4885SMPD1 138/4885 |
| US-20160058786-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20070202054-A1 | Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20230233638-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, SDCBP, PYGL | TP53 181/4885FDPS 2767/4885SMPD1 192/4885 |
| US-10799599-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20120136072-A1 | Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof | SAE1, DSC1, SDC4 | TP53 879/4885FDPS 1852/4885SMPD1 243/4885 |
| US-20180326090-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20100291056-A1 | Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same | P2RY6, GP6, PFKP | TP53 2392/4885FDPS 10/4885SMPD1 138/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | TP53 2173/4885FDPS 449/4885SMPD1 125/4885 |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | STS, RORC, HSD11B1 | TP53 3486/4885FDPS 2059/4885SMPD1 224/4885 |
| US-10512697-B2 | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | TPMT, GSTP1, ALB | TP53 1010/4885FDPS 651/4885SMPD1 4187/4885 |
| US-20140046061-A1 | Processes Employing Cyclodextrin Derivative Quaternary Salts | PICALM, SI, PDCD2L | TP53 3057/4885FDPS 1600/4885SMPD1 3708/4885 |
| US-10668160-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | TP53 1837/4885FDPS 2349/4885SMPD1 219/4885 |
| US-11464862-B2 | DPI formulation containing sulfoalkyl ether cyclodextrin | DSP, DSC1, SAE1 | TP53 1837/4885FDPS 2349/4885SMPD1 219/4885 |
| US-20070020196-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension | SAE1, STS, PDCD2L | TP53 3058/4885FDPS 2018/4885SMPD1 202/4885 |
| US-20090270348-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | TP53 1262/4885FDPS 2080/4885SMPD1 98/4885 |
| US-20130129700-A1 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20150050355-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | SAE1, SDC4, SPECC1L | TP53 787/4885FDPS 1979/4885SMPD1 262/4885 |
| US-10117951-B2 | Sulfoalkyl ether cyclodextrin compositions | SI, SULT1E1, SAE1 | TP53 1509/4885FDPS 2585/4885SMPD1 107/4885 |
| US-20100292268-A1 | Formulations Containing Clopidogrel and Sulfoalkyl Ether Cyclodextrin and Methods of Use | CYP2C19, CYP2C9, CYP3A7 | TP53 1862/4885FDPS 1163/4885SMPD1 95/4885 |
| US-20190169316-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS AND METHODS OF PREPARATION THEREOF | SAE1, SDC4, SPECC1L | TP53 787/4885FDPS 1979/4885SMPD1 262/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | TP53 3704/4885FDPS 3213/4885SMPD1 598/4885 |
| US-20190192684-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20050250738-A1 | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin | SORD, STS, SULT1A1 | TP53 3642/4885FDPS 1241/4885SMPD1 359/4885 |
| US-20100093663-A1 | Sulfoalkyl Ether Cyclodextrin Compositions | SI, SULT1E1, SAE1 | TP53 1509/4885FDPS 2585/4885SMPD1 107/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-10207008-B2 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20160158384-A1 | SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS | SI, SULT1E1, SAE1 | TP53 1509/4885FDPS 2585/4885SMPD1 107/4885 |
| US-20180154015-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | TP53 3486/4885FDPS 2074/4885SMPD1 99/4885 |
| US-20200330539-A1 | COMPOSITIONS CONTAINING SILYMARIN AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USING THE SAME | GYS2, SDCBP, PYGL | TP53 181/4885FDPS 2767/4885SMPD1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.